Last €22.81 EUR
Change Today -0.62 / -2.64%
Volume 95.0
0PT On Other Exchanges
As of 1:03 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

prothena corp plc (0PT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/14 - €36.00
52 Week Low
07/18/14 - €12.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PROTHENA CORP PLC (0PT)

Related News

No related news articles were found.

prothena corp plc (0PT) Related Businessweek News

No Related Businessweek News Found

prothena corp plc (0PT) Details

Prothena Corporation plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel antibodies for the treatment of various diseases associated with protein misfolding or cell adhesion. Its product pipeline includes NEOD001, a product candidate in Phase 1 clinical trial to target AL and AA forms of amyloidosis; PRX002 for the treatment of Parkinson’s disease and related synucleinopathies; and PRX003 for the treatment of inflammatory disease and metastatic cancers. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dublin, Ireland.

39 Employees
Last Reported Date: 03/7/14
Founded in 2012

prothena corp plc (0PT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $462.1K
Chief Financial Officer
Total Annual Compensation: $278.8K
Chief Scientific Officer and Head of Research...
Total Annual Compensation: $349.2K
Compensation as of Fiscal Year 2013.

prothena corp plc (0PT) Key Developments

Prothena Corporation plc Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:00 AM

Prothena Corporation plc Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 09:00 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Gene G. Kinney, Chief Scientific Officer and Head of Research & Development.

Prothena Receives FDA Fast Track Designation for NEOD001, a Monoclonal Antibody for the Treatment of Patients With AL Amyloidosis

Prothena Corporation plc announced that the U.S. Food and Drug Administration granted Fast Track designation to NEOD001, a novel monoclonal antibody for the potential treatment of AL amyloidosis. This is the first investigational immunotherapy specifically targeting the disease-causing protein in AL amyloidosis to receive Fast Track designation. The FDA's Fast Track Drug Development Program is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. An unmet medical need is a condition whose treatment or diagnosis is not addressed adequately by available therapy. The purpose of the Fast Track designation is to make important new drugs available to patients earlier. The Fast Track program also provides a company with the ability to submit sections of the Biologics License Applications (BLA) for review before the company submits the complete BLA. This enables the FDA to review sections of the BLA as they are received, rather than waiting until every section of the application is completed, and also allows for Priority Review, shortening the standard review of the final BLA to six months. A drug program with Fast Track designation permits the company to have early and frequent communications with the FDA in the development and review of the product candidate, potentially to faster drug approval.

Prothena Corporation plc - Special Call

To discuss the new Phase 1/2 study results with NEOD001 for the treatment of AL amyloidosis in addition to the Phase 3 study design for NEOD001


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
0PT:GR €22.81 EUR -0.62

0PT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 0PT.
View Industry Companies

Industry Analysis


Industry Average

Valuation 0PT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.7x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTHENA CORP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at